Literature DB >> 2996399

A human T-lymphotropic retrovirus (HTLV-III) as the cause of the acquired immunodeficiency syndrome.

R C Gallo, F Wong-Staal.   

Abstract

Three human T-lymphotropic viruses have been isolated and characterized in the past 5 years. The ability to culture target cells with T-cell growth factor and sensitive detection systems for the virally encoded polymerase reverse transcriptase permitted isolation of HTLV-I, which is strongly linked to the cause of adult T-cell leukemia and associated with other lymphoid malignancies in endemic areas. The same techniques, using a permissive human tumor cell line, allowed the isolation and characterization of HTLV-III/lymphadenopathy-associated virus, which is implicated as the primary cause of the acquired immunodeficiency syndrome (AIDS). This virus shares some features with HTLV-I and HTLV-II, such as additional genes not found in most retroviruses. One gene codes for a transcriptional activator protein and may be a feature of a larger group of related retroviruses. The clear identification of the primary cause of AIDS has resulted in the development of specific immunologic reagents, preventive and therapeutic proposals, and comprehensive identification of the clinical diseases associated with this virus.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome--etiology; Americas; Antibodies; Biology; Developed Countries; Developing Countries; Diseases; Examinations And Diagnoses; Hiv Infections; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Literature Review; North America; Northern America; Physiology; United States; Viral Diseases--etiology

Mesh:

Substances:

Year:  1985        PMID: 2996399     DOI: 10.7326/0003-4819-103-5-679

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy.

Authors:  P Biberfeld; K J Chayt; L M Marselle; G Biberfeld; R C Gallo; M E Harper
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

Review 2.  Practical diagnostic testing for human immunodeficiency virus.

Authors:  J B Jackson; H H Balfour
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

3.  Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.

Authors:  S Kennedy-Stoskopf; O Narayan
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

Review 4.  Immunodeficiency of aging.

Authors:  E A Burns; J S Goodwin
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 4.271

Review 5.  Zalcitabine. Clinical pharmacokinetics and efficacy.

Authors:  D Devineni; J M Gallo
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 6.  Vaccine and antiviral strategies against infections caused by human immunodeficiency virus.

Authors:  M A Wainberg; O Kendall; N Gilmore
Journal:  CMAJ       Date:  1988-05-01       Impact factor: 8.262

7.  Applying the criteria for the development of health promotion and education programs to AIDS risk reduction programs for gay men.

Authors:  R O Valdiserri; D W Lyter; L C Leviton; K Stoner; A Silvestre
Journal:  J Community Health       Date:  1987

8.  Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections.

Authors:  D M Mwaengo; F J Novembre
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 9.  The neuropathology of AIDS. UCLA experience and review.

Authors:  K H Anders; W F Guerra; U Tomiyasu; M A Verity; H V Vinters
Journal:  Am J Pathol       Date:  1986-09       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.